Oral peptides face a century-old scientific challenge: the digestive system breaks them down before they can reach the bloodstream. Novo Nordisk achieved a breakthrough with their oral semaglutide using SNAC technology, but only after 15 years of development and nine decades of failed attempts dating back to 1922's oral insulin trials.

SNAC works by buffering stomach pH, preventing peptide aggregation, and temporarily fluidizing cell membranes. Despite this innovation, the resulting 0.8% bioavailability means 99.2% of what's ingested gets destroyed. This represents a significant improvement over historical attempts but remains far from ideal therapeutic delivery.

Hims now offers an oral semaglutide pill using "liposomal technology" without published clinical data or human trials. While the company positioned this as a solution during drug shortages, experts question whether patients receive actual treatment or a placebo, especially when no pharmacokinetic studies validate the claimed absorption mechanism.